T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
15 Maio 2023 - 5:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, announced today it has postponed its first quarter 2023
earnings release and conference call. The delay is a result of
additional time required to finalize the filing of the Company's
SEC Form 10-Q.
The Company plans to file a timely Notification
Late Filing on Form 12b-25 to extend the filing deadline for the
Company’s Quarterly Report on Form 10-Q for the quarter
ended March 31, 2023. A press release will be issued
announcing the new date and time for the postponed earnings release
and conference call.
About T2 Biosystems:T2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Biothreat™ Panel, the T2Cauris™
Panel, and T2Lyme™ Panel, as well as next-generation products for
the detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers. For more information, please
visit www.t2biosystems.com.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024